Loading clinical trials...
Loading clinical trials...
Randomized Phase II Trial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab in Locally Advanced Cervical Cancer
Conditions
Interventions
Atezolizumab
Radiotherapy
+1 more
Locations
1
France
Gustave Roussy
Villejuif, Val De Marne, France
Start Date
August 13, 2018
Primary Completion Date
February 26, 2024
Completion Date
May 13, 2025
Last Updated
June 3, 2025
NCT05975593
NCT07104149
NCT05378087
NCT05950087
NCT05311566
NCT06943833
Lead Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions